Ziopharm Oncology Inc (NASDAQ:ZIOP) Sellers Rose Their Shorts By 0.09% As Of Jun 29, 2018

June 29, 2018 - By Leslie Harms

It was reported an increase on Ziopharm Oncology Inc (NASDAQ:ZIOP)’s short interest with 0.09%. In June was issued ZIOP’s total 35.65 million short interest by FINRA. The up change of 0.09% from 35.62 million shares was reported. Previous ZIOP’s position will need 48 days to recover. It has 751,200 average volume. Ziopharm Oncology Inc float short is 32.78%.

The stock decreased 1.95% or $0.06 during the last trading session, touching $3.01.ZIOPHARM Oncology, Inc. has volume of 572,478 shares. Since June 29, 2017 ZIOP has declined 31.35% and is downtrending. ZIOP underperformed by 43.92% the S&P 500.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.The firm is valued at $424.01 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma .Currently it has negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

In total 2 analysts cover Ziopharm Oncology (NASDAQ:ZIOP). “Buy” rating has 1, “Sell” are 1, while 0 are “Hold”. (NASDAQ:ZIOP) has 50% bullish analysts. 3 are the (NASDAQ:ZIOP)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Monday, June 18 the rating was downgraded by JP Morgan to “Underweight”. On Monday, May 14 the rating was maintained by H.C. Wainwright with “Buy”. In Monday, March 5 report H.C. Wainwright maintained it with “Buy” rating and $9.5 target.

For more ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news posted briefly go to: Seekingalpha.com, Fool.com, Streetinsider.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “Ziopharm +1.6% after enrolling first patient in glioblastoma study” posted on June 28, 2018, “Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics” on June 29, 2018, “After-Hours Stock Movers 06/28: (GEMP) (NKE) (VRTX) Higher; (SNX) (CVG) Lower (more…)” with a publish date: June 28, 2018, “Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19 …” and the last “Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher” with publication date: June 18, 2018.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: